Colorectal Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Ann Surg Oncol. 2013 Apr;20(4):1179-84. doi: 10.1245/s10434-012-2722-7. Epub 2013 Jan 18.
The circumferential resection margin (CRM) is highly prognostic for local recurrence in rectal cancer surgery without neoadjuvant treatment. However, its significance in the setting of long-course neoadjuvant chemoradiotherapy (nCRT) is not well defined.
Review of a single institution's prospectively maintained database from 1998 to 2007 identified 563 patients with locally advanced rectal cancer (T3/T4 and/or N1) receiving nCRT, followed after 6 weeks by total mesorectal excision (TME). Kaplan-Meier, Cox regression, and competing risk analysis were performed.
The authors noted that 75 % of all patients had stage III disease as determined by endorectal ultrasound (ERUS) and/or magnetic resonance imaging (MRI). With median follow-up of 39 months after resection, local and distant relapse were noted in 12 (2.1 %) and 98 (17.4 %) patients, respectively. On competing risk analysis, the optimal cutoff point of CRM was 1 mm for local recurrence and 2 mm for distant metastasis. Factors independently associated with local recurrence included CRM ≤1 mm, and high-grade tumor (p = 0.012 and 0.007, respectively). CRM ≤2 mm, as well as pathological, nodal, and overall tumor stage are also significant independent risk factors for distant metastasis (p = 0.025, 0.010, and <0.001, respectively).
In this dataset of locally advanced rectal cancer treated with nCRT followed by TME, CRM ≤1 mm is an independent risk factor for local recurrence and is considered a positive margin. CRM ≤2 mm was associated with distant recurrence, independent of pathological tumor and nodal stage.
在未接受新辅助治疗的直肠癌手术中,环周切缘(CRM)与局部复发高度相关。然而,在长程新辅助放化疗(nCRT)的情况下,其意义尚不清楚。
回顾 1998 年至 2007 年期间单机构前瞻性维护的数据库,确定了 563 例接受 nCRT 的局部进展期直肠癌(T3/T4 和/或 N1)患者,在 6 周后行全直肠系膜切除术(TME)。采用 Kaplan-Meier、Cox 回归和竞争风险分析。
作者指出,所有患者中有 75%根据直肠内超声(ERUS)和/或磁共振成像(MRI)确定为 III 期疾病。在切除后中位随访 39 个月后,分别有 12(2.1%)和 98(17.4%)例患者出现局部和远处复发。在竞争风险分析中,CRM 用于局部复发的最佳截断值为 1mm,用于远处转移的最佳截断值为 2mm。与局部复发独立相关的因素包括 CRM≤1mm 和高级别肿瘤(p=0.012 和 0.007)。CRM≤2mm 以及病理、淋巴结和总肿瘤分期也是远处转移的独立危险因素(p=0.025、0.010 和<0.001)。
在接受 nCRT 后行 TME 治疗的局部进展期直肠癌患者中,CRM≤1mm 是局部复发的独立危险因素,被视为阳性切缘。CRM≤2mm 与远处复发相关,与病理肿瘤和淋巴结分期无关。